Eli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, a significant...

Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The...

Eli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...

Gurugram authorities uncovered a counterfeit Mounjaro operation. Police seized fake diabetes and weight loss injections valued at ₹70 lakh....

Gurugram's law enforcement has taken a bold step by breaking up a ring creating counterfeit Mounjaro injections, with two individuals now i...

Mounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...

LLY stock today: Eli Lilly's stock saw a significant jump following impressive fourth-quarter results and a strong 2026 financial forecast....

Eli Lilly's diabetes drug Mounjaro will be added to China's state health insurance from January 1, making it more accessible to the country...

Eli Lilly stock today: Eli Lilly achieved a historic milestone, briefly touching a $1 trillion market cap. This success is driven by strong...

Eli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will be sold under ...

Lilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales within ...

Lilly stock latest news: Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year gu...

Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, reducing mortality a...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, recently launched i...

Eli Lilly will launch Mounjaro in India in 2025. The drug treats type 2 diabetes and obesity. Lilly received marketing authorization in Jul...

Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales...

SVB Securities believes that the new diabetes drug by Eli Lilly might be able to address patients' obesity and might lead to more significa...